DAIC

FEBRUARY 29, 2024

ET Main Tent (Hall B1) Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

European Journal of Heart Failure

APRIL 13, 2025

The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Pulmonary Peripheral Arterial Disease 40

DAIC

MARCH 26, 2025

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 4 Approximately 6.7

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

European Journal of Heart Failure

APRIL 6, 2025

During a median follow-up of 12.6years, 349 (4.3%) HF events occurred of which 118 (33.8%) had HF with preserved ejection fraction. Methods and results We included a total of 8199 individuals from the Prevention of REnal and Vascular End-stage Disease (PREVEND) community-based cohort (mean age: 49.8years; 50.1%

Heart Failure 40

Heart Failure Preserved Ejection Fraction Cholesterol Obesity 40

Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. The study analyzed the effects of semaglutide 2.4

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

DAIC

MARCH 29, 2024

HFpEF is HF with preserved ejection fraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle. This type of HF is largely associated with obesity and hypertension. There are two types of HF.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Quality of Life Hospital 111

Journal of the American Heart Association

JANUARY 23, 2025

BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Journal of the American Heart Association, Ahead of Print. Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2.

Heart Failure 45

Heart Failure Preserved Ejection Fraction Obesity Outcomes 45

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59

Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103